# EDGAR Filing Document

**Accession Number:** 0001559109
**File Stem:** 0001752724-23-073260
**Filing Date:** 2023-3
**Character Count:** 27959
**Document Hash:** 4e4e39258be6567f1ed8d3b5f61bf3c9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001752724-23-073260.hdr.sgml**: 20230330

**ACCESSION NUMBER**: 0001752724-23-073260

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230131

**FILED AS OF DATE**: 20230330

**DATE AS OF CHANGE**: 20230330

**PERIOD START**: 20231031

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ETFis Series Trust I
- **CENTRAL INDEX KEY:** 0001559109
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-22819
- **FILM NUMBER:** 23778029

**BUSINESS ADDRESS:**
- **STREET 1:** 1540 BROADWAY
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 347-903-7347

**MAIL ADDRESS:**
- **STREET 1:** 1540 BROADWAY
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ETF Actively Managed Trust
- **DATE OF NAME CHANGE:** 20120926

## Series and Classes Contracts Data

### Virtus LifeSci Biotech Products ETF (Series ID: S000047354)

| Class ID   | Class Name                          | Ticker Symbol   |
|:---|:---|:---|
| C000148682 | Virtus LifeSci Biotech Products ETF | BBP             |

## Nport-Ex

Schedule of Investments - Virtus LifeSci Biotech Products ETF

January 31, 2023 (unaudited)

---

| | | |
|:---|:---|:---|
| **Security Description** | **Shares** | **Value** |
| **COMMON STOCKS - 98.9%** |  |  |
| **Health Care - 98.9%** |  |  |
| 2seventy bio, Inc.\* | 24598 | $334533 |
| ACADIA Pharmaceuticals, Inc.\* | 19173 | 364862 |
| ADMA Biologics, Inc.\* | 82439 | 304200 |
| Agios Pharmaceuticals, Inc.\* | 9753 | 287518 |
| Alnylam Pharmaceuticals, Inc.\* | 1293 | 292735 |
| Amgen, Inc. | 1116 | 281678 |
| Amicus Therapeutics, Inc.\* | 24301 | 316885 |
| Amylyx Pharmaceuticals, Inc.\* | 8307 | 325551 |
| Apellis Pharmaceuticals, Inc.\* | 5743 | 302828 |
| Ascendis Pharma A/S (Denmark)\*<sup>(1)</sup> | 2491 | 309083 |
| Aurinia Pharmaceuticals, Inc. (Canada)\* | 64786 | 586313 |
| Axsome Therapeutics, Inc.\* | 3795 | 284625 |
| BeiGene Ltd. (China)\*<sup>(1)(2)</sup> | 1446 | 370176 |
| BioCryst Pharmaceuticals, Inc.\*<sup>(2)</sup> | 27086 | 285757 |
| Biogen, Inc.\* | 1047 | 304572 |
| BioMarin Pharmaceutical, Inc.\* | 2792 | 322057 |
| BioNTech SE (Germany)<sup>(1)</sup> | 1626 | 233185 |
| Bluebird Bio, Inc.\* | 36147 | 229533 |
| Blueprint Medicines Corp.\* | 6474 | 302595 |
| Bridgebio Pharma, Inc.\*<sup>(2)</sup> | 31681 | 294000 |
| CTI BioPharma Corp.\* | 51542 | 285027 |
| Deciphera Pharmaceuticals, Inc.\* | 19052 | 324075 |
| Enanta Pharmaceuticals, Inc.\* | 6800 | 362984 |
| Exelixis, Inc.\* | 18688 | 329283 |
| Gilead Sciences, Inc. | 3423 | 287327 |
| Halozyme Therapeutics, Inc.\* | 5170 | 267651 |
| Harmony Biosciences Holdings, Inc.\* | 5159 | 248509 |
| Immunocore Holdings PLC (United Kingdom)\*<sup>(1)</sup> | 5131 | 314376 |
| ImmunoGen, Inc.\* | 58521 | 269197 |
| Incyte Corp.\* | 3660 | 311612 |
| Insmed, Inc.\* | 15135 | 325857 |
| Intercept Pharmaceuticals, Inc.\* | 20251 | 369783 |
| Intra-Cellular Therapies, Inc.\* | 5733 | 274725 |
| Ionis Pharmaceuticals, Inc.\* | 7900 | 314973 |
| Ironwood Pharmaceuticals, Inc.\*<sup>(2)</sup> | 24399 | 281077 |
| Kiniksa Pharmaceuticals Ltd. Class A\* | 19345 | 279729 |
| Legend Biotech Corp.\*<sup>(1)</sup> | 5832 | 294516 |
| Ligand Pharmaceuticals, Inc.\* | 4721 | 329054 |
| Mirum Pharmaceuticals, Inc.\* | 16790 | 394229 |
| Moderna, Inc.\* | 1448 | 254935 |
| Myovant Sciences Ltd.\* | 11251 | 302427 |
| Nektar Therapeutics\* | 110420 | 300342 |
| Neurocrine Biosciences, Inc.\* | 2537 | 281429 |
| Omniab, Inc.\* | 1295 | 0 |
| Omniab, Inc.\* | 1295 | 0 |
| Provention Bio, Inc.\* | 31095 | 269283 |
| PTC Therapeutics, Inc.\* | 7648 | 350967 |
| Regeneron Pharmaceuticals, Inc.\* | 403 | 305663 |
| Rhythm Pharmaceuticals, Inc.\* | 10221 | 279544 |
| Roivant Sciences Ltd.\* | 41905 | 347812 |
| Sage Therapeutics, Inc.\* | 7320 | 324569 |
| Sarepta Therapeutics, Inc.\* | 2395 | 299303 |
| Seagen, Inc.\* | 2291 | 319549 |
| Theravance Biopharma, Inc.\* | 26989 | 291751 |
| Travere Therapeutics, Inc.\*<sup>(2)</sup> | 16381 | 366934 |
| Ultragenyx Pharmaceutical, Inc.\* | 6655 | 301671 |
| United Therapeutics Corp.\* | 1093 | 287645 |
| Vanda Pharmaceuticals, Inc.\* | 41789 | 320940 |
| Vertex Pharmaceuticals, Inc.\* | 969 | 313084 |
| Zai Lab Ltd. (China)\*<sup>(1)</sup> | 8625 | 363458 |
| **TOTAL INVESTMENTS - 98.9%** |  |  |
| (Cost $17,745,284) |  | **18077976** |
| Other Assets in Excess of Liabilities - 1.1% |  | 207193 |
| **Net Assets - 100.0%** |  | $**18285169** |

---

\* Non-income producing security.

(1) American Depositary Receipts.

(2) All or a portion of the security was on loan. The aggregate market value of securities on loan was $1,365,770; total market value of collateral held by the Fund was $1,361,121. Market value of the collateral held includes non-cash U.S. Treasury securities having a value of $1,361,121.

Schedule of Investments - Virtus LifeSci Biotech Products ETF (continued)

January 31, 2023 (unaudited)

---

| |
|:---|
| **Fair Value Measurements** |
| The Fund utilizes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 includes unadjusted quoted prices in active markets for identical assets or liabilities that the Fund has the ability to access. Level 2 includes observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar securities, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data. Level 3 includes unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available; representing the Fund's own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available. The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. |
| <br> The following table summarizes valuation of the Fund's investments under the fair value hierarchy levels as of January 31, 2023. |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Level 1** | **Level 2** | **Level 3** | **Total** |
| **Asset Valuation Inputs** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Common Stocks | $18077976 | $0 | $— | $18077976 |
| Total | $18077976 | $0 | $— | $18077976 |

---

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** ETFis Series Trust I

- **b. Investment Company Act file number:** 811-22819

- **c. CIK number of Registrant:** 0001559109

- **d. LEI of Registrant:** 5493002CWTVLBPSYFT98

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 31 West 52nd Street

  - **City:** New York

  - **State:** NY

  - **Foreign country:** US

  - **Zip / Postal Code:** 10019

  - **Telephone number:** 347-903-7347

**Item A.2. Information about the Series.**

- **a. Name of Series:** Virtus LifeSci Biotech Products ETF

- **b. EDGAR series identifier (if any):** S000047354

- **c. LEI of Series:** 549300U4V8YBNY7O1032

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2023-10-31

- **b. Date as of which information is reported:** 2023-01-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $18318452.36

**Total Liabilities:** $33282.44

**Net Assets:** $18285169.92

**Cash Not Reported:** $239756.83

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000148682 | 7.54%                | -1.73%               | 5.83%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $-5.95                   | $1240781.74                                |
| Month 2  | $151202.03               | $-447024.15                                |
| Month 3  | $2.37                    | $1018495.67                                |

### Schedule of Portfolio Investments

| Name                           | Title                            | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Travere Therapeutics Inc       | Travere Therapeutics Inc         | CUSIP: 89422G107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     16381 | NS      | $366934.40    | 2.01%             |  |  |  | No            |                  1 | On Loan: —       |
| ADMA Biologics Inc             | ADMA Biologics Inc               | CUSIP: 000899104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     82439 | NS      | $304199.91    | 1.66%             |  |  |  | No            |                  1 | On Loan: No      |
| Legend Biotech Corp            | Legend Biotech Corp              | CUSIP: 52490G102<br>LEI: 254900EIUFZTW136H859 | Long             | EC               | CORP              | US        |      5832 | NS      | $294516.00    | 1.61%             |  |  |  | No            |                  1 | On Loan: No      |
| CTI BioPharma Corp             | CTI BioPharma Corp               | CUSIP: 12648L601<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     51542 | NS      | $285027.26    | 1.56%             |  |  |  | No            |                  1 | On Loan: No      |
| Bridgebio Pharma Inc           | Bridgebio Pharma Inc             | CUSIP: 10806X102<br>LEI: 54930028YG89VTY2J114 | Long             | EC               | CORP              | US        |     31681 | NS      | $293999.68    | 1.61%             |  |  |  | No            |                  1 | On Loan: —       |
| Provention Bio Inc             | Provention Bio Inc               | CUSIP: 74374N102<br>LEI: 5493003LM26XAVJKLD34 | Long             | EC               | CORP              | US        |     31095 | NS      | $269282.70    | 1.47%             |  |  |  | No            |                  1 | On Loan: No      |
| IONIS PHARMACEUTICALS INC      | IONIS PHARMACEUTICALS INC        | CUSIP: 462222100<br>LEI: 549300SI4ZGLG0BLUZ92 | Long             | EC               | CORP              | US        |      7900 | NS      | $314973.00    | 1.72%             |  |  |  | No            |                  1 | On Loan: No      |
| ULTRAGENYX PHARMACEUTICAL IN   | ULTRAGENYX PHARMACEUTICAL INC    | CUSIP: 90400D108<br>LEI: 529900EV44GVDN1DCX77 | Long             | EC               | CORP              | US        |      6655 | NS      | $301671.15    | 1.65%             |  |  |  | No            |                  1 | On Loan: No      |
| BIOMARIN PHARMACEUTICAL INC    | BIOMARIN PHARMACEUTICAL INC      | CUSIP: 09061G101<br>LEI: NSLL8ITTRR0J5HEMR848 | Long             | EC               | CORP              | US        |      2792 | NS      | $322057.20    | 1.76%             |  |  |  | No            |                  1 | On Loan: No      |
| Apellis Pharmaceuticals Inc    | Apellis Pharmaceuticals Inc      | CUSIP: 03753U106<br>LEI: 254900HS0ZFRXXSB9D42 | Long             | EC               | CORP              | US        |      5743 | NS      | $302828.39    | 1.66%             |  |  |  | No            |                  1 | On Loan: No      |
| ACADIA Pharmaceuticals Inc     | ACADIA Pharmaceuticals Inc       | CUSIP: 004225108<br>LEI: 529900O3044NO0PEA039 | Long             | EC               | CORP              | US        |     19173 | NS      | $364862.19    | 2.00%             |  |  |  | No            |                  1 | On Loan: No      |
| IRONWOOD PHARMACEUTICALS INC   | IRONWOOD PHARMACEUTICALS INC     | CUSIP: 46333X108<br>LEI: 549300PC8MR6QHH6P296 | Long             | EC               | CORP              | US        |     24399 | NS      | $281076.48    | 1.54%             |  |  |  | No            |                  1 | On Loan: —       |
| BeiGene Ltd                    | BeiGene Ltd                      | CUSIP: 07725L102<br>LEI: 549300JFUK6FRD5MH739 | Long             | EC               | CORP              | US        |      1446 | NS      | $370176.00    | 2.02%             |  |  |  | No            |                  1 | On Loan: —       |
| Rhythm Pharmaceuticals Inc     | Rhythm Pharmaceuticals Inc       | CUSIP: 76243J105<br>LEI: 529900JPNWXQ8DPLA551 | Long             | EC               | CORP              | US        |     10221 | NS      | $279544.35    | 1.53%             |  |  |  | No            |                  1 | On Loan: No      |
| Omniab Inc/old                 | Omniab Inc/old                   | CUSIP: 68218J202<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1295 | NS      | $0.00         | 0.00%             |  |  |  | No            |                  2 | On Loan: No      |
| Omniab Inc/old                 | Omniab Inc/old                   | CUSIP: 68218J301<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1295 | NS      | $0.00         | 0.00%             |  |  |  | No            |                  2 | On Loan: No      |
| INCYTE CORP                    | INCYTE CORP                      | CUSIP: 45337C102<br>LEI: 549300Z4WN6JVZ3T4680 | Long             | EC               | CORP              | US        |      3660 | NS      | $311612.40    | 1.70%             |  |  |  | No            |                  1 | On Loan: No      |
| Harmony Biosciences Holdings I | Harmony Biosciences Holdings Inc | CUSIP: 413197104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      5159 | NS      | $248509.03    | 1.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Insmed Inc                     | Insmed Inc                       | CUSIP: 457669307<br>LEI: 529900Q55QAG41CCAC11 | Long             | EC               | CORP              | US        |     15135 | NS      | $325856.55    | 1.78%             |  |  |  | No            |                  1 | On Loan: No      |
| NEKTAR THERAPEUTICS            | NEKTAR THERAPEUTICS              | CUSIP: 640268108<br>LEI: 5299005I24806IOIYE03 | Long             | EC               | CORP              | US        |    110420 | NS      | $300342.40    | 1.64%             |  |  |  | No            |                  1 | On Loan: No      |
| PTC Therapeutics Inc           | PTC Therapeutics Inc             | CUSIP: 69366J200<br>LEI: 549300UJLWOIWFDGB318 | Long             | EC               | CORP              | US        |      7648 | NS      | $350966.72    | 1.92%             |  |  |  | No            |                  1 | On Loan: No      |
| Axsome Therapeutics Inc        | Axsome Therapeutics Inc          | CUSIP: 05464T104<br>LEI: 549300EXGR0XLRJEIB95 | Long             | EC               | CORP              | US        |      3795 | NS      | $284625.00    | 1.56%             |  |  |  | No            |                  1 | On Loan: No      |
| Alnylam Pharmaceuticals Inc    | Alnylam Pharmaceuticals Inc      | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |      1293 | NS      | $292735.20    | 1.60%             |  |  |  | No            |                  1 | On Loan: No      |
| THERAVANCE BIOPHARMA INC       | THERAVANCE BIOPHARMA INC         | CUSIP: 000000000<br>LEI: 5493007VTSXP4Z6MIW52 | Long             | EC               | CORP              | KY        |     26989 | NS      | $291751.09    | 1.60%             |  |  |  | No            |                  1 | On Loan: No      |
| Mirum Pharmaceuticals Inc      | Mirum Pharmaceuticals Inc        | CUSIP: 604749101<br>LEI: 254900YZKR40F7F27K81 | Long             | EC               | CORP              | US        |     16790 | NS      | $394229.20    | 2.16%             |  |  |  | No            |                  1 | On Loan: No      |
| Deciphera Pharmaceuticals Inc  | Deciphera Pharmaceuticals Inc    | CUSIP: 24344T101<br>LEI: 529900QR4WAPYY0CBF25 | Long             | EC               | CORP              | US        |     19052 | NS      | $324074.52    | 1.77%             |  |  |  | No            |                  1 | On Loan: No      |
| Kiniksa Pharmaceuticals Ltd    | Kiniksa Pharmaceuticals Ltd      | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     19345 | NS      | $279728.70    | 1.53%             |  |  |  | No            |                  1 | On Loan: No      |
| Amgen Inc                      | Amgen Inc                        | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |      1116 | NS      | $281678.40    | 1.54%             |  |  |  | No            |                  1 | On Loan: No      |
| Zai Lab Ltd                    | Zai Lab Ltd                      | CUSIP: 98887Q104<br>LEI: 549300P2UYQ9U5LY1T58 | Long             | EC               | CORP              | CN        |      8625 | NS      | $363457.50    | 1.99%             |  |  |  | No            |                  1 | On Loan: No      |
| Blueprint Medicines Corp       | Blueprint Medicines Corp         | CUSIP: 09627Y109<br>LEI: 5299004CC60O9T5HVM83 | Long             | EC               | CORP              | US        |      6474 | NS      | $302594.76    | 1.65%             |  |  |  | No            |                  1 | On Loan: No      |
| SAREPTA THERAPEUTICS INC       | SAREPTA THERAPEUTICS INC         | CUSIP: 803607100<br>LEI: 549300IKDPIED8J8IG21 | Long             | EC               | CORP              | US        |      2395 | NS      | $299303.15    | 1.64%             |  |  |  | No            |                  1 | On Loan: No      |
| VERTEX PHARMACEUTICALS INC     | VERTEX PHARMACEUTICALS INC       | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |       969 | NS      | $313083.90    | 1.71%             |  |  |  | No            |                  1 | On Loan: No      |
| Myovant Sciences Ltd           | Myovant Sciences Ltd             | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | GB        |     11251 | NS      | $302426.88    | 1.65%             |  |  |  | No            |                  1 | On Loan: No      |
| BIOGEN INC                     | BIOGEN INC                       | CUSIP: 09062X103<br>LEI: W8J5WZB5IY3K0NDQT671 | Long             | EC               | CORP              | US        |      1047 | NS      | $304572.30    | 1.67%             |  |  |  | No            |                  1 | On Loan: No      |
| ENANTA PHARMACEUTICALS INC     | ENANTA PHARMACEUTICALS INC       | CUSIP: 29251M106<br>LEI: 529900SSN4DODDQSN594 | Long             | EC               | CORP              | US        |      6800 | NS      | $362984.00    | 1.99%             |  |  |  | No            |                  1 | On Loan: No      |
| BioCryst Pharmaceuticals Inc   | BioCryst Pharmaceuticals Inc     | CUSIP: 09058V103<br>LEI: 549300Z0INP1Z5NP6J59 | Long             | EC               | CORP              | US        |     27086 | NS      | $285757.30    | 1.56%             |  |  |  | No            |                  1 | On Loan: —       |
| Seagen Inc                     | Seagen Inc                       | CUSIP: 81181C104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      2291 | NS      | $319548.68    | 1.75%             |  |  |  | No            |                  1 | On Loan: No      |
| Sage Therapeutics Inc          | Sage Therapeutics Inc            | CUSIP: 78667J108<br>LEI: 5493000JX4BJS9W6CN35 | Long             | EC               | CORP              | US        |      7320 | NS      | $324568.80    | 1.78%             |  |  |  | No            |                  1 | On Loan: No      |
| Aurinia Pharmaceuticals Inc    | Aurinia Pharmaceuticals Inc      | CUSIP: 05156V102<br>LEI: 5299008YP2BW4570ML28 | Long             | EC               | CORP              | CA        |     64786 | NS      | $586313.30    | 3.21%             |  |  |  | No            |                  1 | On Loan: No      |
| REGENERON PHARMACEUTICALS      | REGENERON PHARMACEUTICALS INC    | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |       403 | NS      | $305663.41    | 1.67%             |  |  |  | No            |                  1 | On Loan: No      |
| Amylyx Pharmaceuticals Inc     | Amylyx Pharmaceuticals Inc       | CUSIP: 03237H101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      8307 | NS      | $325551.33    | 1.78%             |  |  |  | No            |                  1 | On Loan: No      |
| NEUROCRINE BIOSCIENCES INC     | NEUROCRINE BIOSCIENCES INC       | CUSIP: 64125C109<br>LEI: 549300FECER0XBN49756 | Long             | EC               | CORP              | US        |      2537 | NS      | $281429.41    | 1.54%             |  |  |  | No            |                  1 | On Loan: No      |
| Intra-Cellular Therapies Inc   | Intra-Cellular Therapies Inc     | CUSIP: 46116X101<br>LEI: 5299002U2KGF193IJA20 | Long             | EC               | CORP              | US        |      5733 | NS      | $274725.36    | 1.50%             |  |  |  | No            |                  1 | On Loan: No      |
| Roivant Sciences Ltd           | Roivant Sciences Ltd             | CUSIP: 000000000<br>LEI: 549300DL466NY5J6U724 | Long             | EC               | CORP              | US        |     41905 | NS      | $347811.50    | 1.90%             |  |  |  | No            |                  1 | On Loan: No      |
| Intercept Pharmaceuticals Inc  | Intercept Pharmaceuticals Inc    | CUSIP: 45845P108<br>LEI: 254900JMB8TX5P688V24 | Long             | EC               | CORP              | US        |     20251 | NS      | $369783.26    | 2.02%             |  |  |  | No            |                  1 | On Loan: No      |
| UNITED THERAPEUTICS CORP       | UNITED THERAPEUTICS CORP         | CUSIP: 91307C102<br>LEI: 5299005C4HZL4UWROC14 | Long             | EC               | CORP              | US        |      1093 | NS      | $287644.81    | 1.57%             |  |  |  | No            |                  1 | On Loan: No      |
| AGIOS PHARMACEUTICALS INC      | AGIOS PHARMACEUTICALS INC        | CUSIP: 00847X104<br>LEI: 529900ONJHY8EOGYT555 | Long             | EC               | CORP              | US        |      9753 | NS      | $287518.44    | 1.57%             |  |  |  | No            |                  1 | On Loan: No      |
| Immunocore Holdings PLC        | Immunocore Holdings PLC          | CUSIP: 45258D105<br>LEI: 213800IUE3DFS84BVN18 | Long             | EC               | CORP              | GB        |      5131 | NS      | $314376.37    | 1.72%             |  |  |  | No            |                  1 | On Loan: No      |
| Amicus Therapeutics Inc        | Amicus Therapeutics Inc          | CUSIP: 03152W109<br>LEI: 549300MRD1SMUTNBPQ53 | Long             | EC               | CORP              | US        |     24301 | NS      | $316885.04    | 1.73%             |  |  |  | No            |                  1 | On Loan: No      |
| Moderna Inc                    | Moderna Inc                      | CUSIP: 60770K107<br>LEI: 549300EI6OKH5K5Q2G38 | Long             | EC               | CORP              | US        |      1448 | NS      | $254934.88    | 1.39%             |  |  |  | No            |                  1 | On Loan: No      |
| ImmunoGen Inc                  | ImmunoGen Inc                    | CUSIP: 45253H101<br>LEI: 54930084U0R1OP766Y02 | Long             | EC               | CORP              | US        |     58521 | NS      | $269196.60    | 1.47%             |  |  |  | No            |                  1 | On Loan: No      |
| 2seventy bio Inc               | 2seventy bio Inc                 | CUSIP: 901384107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     24598 | NS      | $334532.80    | 1.83%             |  |  |  | No            |                  1 | On Loan: No      |
| EXELIXIS INC                   | EXELIXIS INC                     | CUSIP: 30161Q104<br>LEI: 254900PJQB59O2O95R37 | Long             | EC               | CORP              | US        |     18688 | NS      | $329282.56    | 1.80%             |  |  |  | No            |                  1 | On Loan: No      |
| Bluebird Bio Inc               | Bluebird Bio Inc                 | CUSIP: 09609G100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     36147 | NS      | $229533.45    | 1.26%             |  |  |  | No            |                  1 | On Loan: No      |
| BioNTech SE                    | BioNTech SE                      | CUSIP: 09075V102<br>LEI: 894500UZJ5LG1F8J1U58 | Long             | EC               | CORP              | DE        |      1626 | NS      | $233184.66    | 1.28%             |  |  |  | No            |                  1 | On Loan: No      |
| LIGAND PHARMACEUTICALS         | LIGAND PHARMACEUTICALS INC       | CUSIP: 53220K504<br>LEI: 5493008K7TB0IKP37H79 | Long             | EC               | CORP              | US        |      4721 | NS      | $329053.70    | 1.80%             |  |  |  | No            |                  1 | On Loan: No      |
| Ascendis Pharma A/S            | Ascendis Pharma A/S              | CUSIP: 04351P101<br>LEI: 549300B66JN3W3J8GH73 | Long             | EC               | CORP              | DK        |      2491 | NS      | $309083.28    | 1.69%             |  |  |  | No            |                  1 | On Loan: No      |
| GILEAD SCIENCES INC            | GILEAD SCIENCES INC              | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |      3423 | NS      | $287326.62    | 1.57%             |  |  |  | No            |                  1 | On Loan: No      |
| VANDA PHARMACEUTICALS INC      | VANDA PHARMACEUTICALS INC        | CUSIP: 921659108<br>LEI: 529900AY8VOOQBKJ0O70 | Long             | EC               | CORP              | US        |     41789 | NS      | $320939.52    | 1.76%             |  |  |  | No            |                  1 | On Loan: No      |
| HALOZYME THERAPEUTICS INC      | HALOZYME THERAPEUTICS INC        | CUSIP: 40637H109<br>LEI: 529900242I3SV9AGM753 | Long             | EC               | CORP              | US        |      5170 | NS      | $267650.90    | 1.46%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2023-03-22

**Name of Applicant:** ETFis Series Trust I

**Signature:** Brinton W. Frith

**Name of Signer:** Brinton W. Frith

**Title:** Treasurer and Principal Financial Officer